Production (Stage)
Kiora Pharmaceuticals, Inc.
KPRX
$3.08
-$0.01-0.32%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | 50.33% | -33.21% | 21.40% | -34.87% | 284.26% |
| Gross Profit | -117.69% | 33.21% | -21.40% | 36.30% | 3,366.21% |
| SG&A Expenses | 14.89% | 50.68% | -2.46% | 40.16% | 2.12% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -26.34% | 25.80% | 7.89% | -1.80% | 63.38% |
| Operating Income | -115.56% | -25.80% | -7.89% | 2.60% | 873.55% |
| Income Before Tax | -115.39% | 0.91% | 40.77% | 15.00% | 820.00% |
| Income Tax Expenses | -- | 2,186.82% | -- | -- | -- |
| Earnings from Continuing Operations | -116.30% | -86.17% | 40.77% | 15.00% | 820.00% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -116.30% | -86.17% | 40.77% | 15.00% | 820.00% |
| EBIT | -115.56% | -25.80% | -7.89% | 2.60% | 873.55% |
| EBITDA | -115.55% | -26.00% | -8.30% | 1.97% | 878.39% |
| EPS Basic | -111.14% | 63.10% | 89.84% | 92.55% | 151.73% |
| Normalized Basic EPS | -109.12% | 80.49% | 79.95% | 92.54% | 158.19% |
| EPS Diluted | -115.03% | 63.12% | 89.84% | 92.55% | 138.34% |
| Normalized Diluted EPS | -112.32% | 80.49% | 79.95% | 92.54% | 143.09% |
| Average Basic Shares Outstanding | 46.33% | 404.57% | 433.75% | 1,041.07% | 1,291.50% |
| Average Diluted Shares Outstanding | 8.36% | 404.57% | 433.75% | 1,041.07% | 1,779.14% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |